MX2023001734A - Métodos para prevenir y tratar la disfunción cardíaca y el covid-19 con antagonistas de activina a. - Google Patents

Métodos para prevenir y tratar la disfunción cardíaca y el covid-19 con antagonistas de activina a.

Info

Publication number
MX2023001734A
MX2023001734A MX2023001734A MX2023001734A MX2023001734A MX 2023001734 A MX2023001734 A MX 2023001734A MX 2023001734 A MX2023001734 A MX 2023001734A MX 2023001734 A MX2023001734 A MX 2023001734A MX 2023001734 A MX2023001734 A MX 2023001734A
Authority
MX
Mexico
Prior art keywords
methods
preventing
activin
treating cardiac
covid
Prior art date
Application number
MX2023001734A
Other languages
English (en)
Spanish (es)
Inventor
David Glass
Lori Morton
Scott Macdonnell
Jake Megna
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023001734A publication Critical patent/MX2023001734A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2023001734A 2020-08-20 2021-08-19 Métodos para prevenir y tratar la disfunción cardíaca y el covid-19 con antagonistas de activina a. MX2023001734A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063068251P 2020-08-20 2020-08-20
US202063111394P 2020-11-09 2020-11-09
US202163139234P 2021-01-19 2021-01-19
PCT/US2021/046765 WO2022040461A1 (en) 2020-08-20 2021-08-19 Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists

Publications (1)

Publication Number Publication Date
MX2023001734A true MX2023001734A (es) 2023-03-31

Family

ID=77774983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001734A MX2023001734A (es) 2020-08-20 2021-08-19 Métodos para prevenir y tratar la disfunción cardíaca y el covid-19 con antagonistas de activina a.

Country Status (10)

Country Link
US (2) US20220056119A1 (enExample)
EP (1) EP4200017A1 (enExample)
JP (1) JP2023539107A (enExample)
KR (1) KR20230051683A (enExample)
CN (1) CN116249713A (enExample)
AU (1) AU2021327238A1 (enExample)
CA (1) CA3189147A1 (enExample)
IL (1) IL300362A (enExample)
MX (1) MX2023001734A (enExample)
WO (1) WO2022040461A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
PE20120532A1 (es) 2009-04-27 2012-05-18 Novartis Ag ANTICUERPOS ANTI-ActRIIB
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
CA2983440C (en) * 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
WO2018009732A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
CA3052625A1 (en) * 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
LT3600415T (lt) * 2017-03-24 2025-12-29 Novartis Ag Antikūnas prieš ii tipo aktivino receptorių, skirtas naudoti širdies nepakankamumo gydymui
WO2019005963A1 (en) * 2017-06-27 2019-01-03 The University Of Chicago USE OF ACTIVIN TO DETECT POST-PARTUM CARDIAC DYSFUNCTION

Also Published As

Publication number Publication date
EP4200017A1 (en) 2023-06-28
CA3189147A1 (en) 2022-02-24
US20250277021A1 (en) 2025-09-04
IL300362A (en) 2023-04-01
US20220056119A1 (en) 2022-02-24
JP2023539107A (ja) 2023-09-13
CN116249713A (zh) 2023-06-09
WO2022040461A1 (en) 2022-02-24
AU2021327238A1 (en) 2023-04-27
AU2021327238A9 (en) 2024-06-06
KR20230051683A (ko) 2023-04-18

Similar Documents

Publication Publication Date Title
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
MX2008000984A (es) Metodos para reducir la carga viral en pacientes infectados con vih-1.
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
EA201170157A1 (ru) Notch-связывающие агенты и антагонисты и способы их применения
AR058135A1 (es) Agentes para el tratamiento de cardiopatias
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
JP2019510739A5 (enExample)
PE20081635A1 (es) Agentes para suprimir la reaccion de rechazo cronica
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
WO2021016571A3 (en) Methods of treating antibody-mediated disorders with fcrn antagonists
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
MX2023001734A (es) Métodos para prevenir y tratar la disfunción cardíaca y el covid-19 con antagonistas de activina a.
JP2017520562A5 (enExample)
WO2018102670A3 (en) Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down
Novello et al. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non–small-cell lung cancer: results from the randomized controlled MONET1 study
EA202190755A1 (ru) Агенты для терапии и диагностики рака
Cheng et al. Sildenafil monotherapy to treat portopulmonary hypertension before liver transplant
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
Godse Omalizumab in treatment-resistant chronic spontaneous urticaria
MX2022001411A (es) Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5.
TW200738264A (en) Synergistic compositions for treating HIV
WO2024112527A3 (en) Methods for the treatment of thyroid eye disease
Das et al. Alemtuzumab (Campath‐1H) therapy for refractory rejections in pediatric heart transplant recipients